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The automatic implantable cardioverter-defibrillator 
continuously monitors the heart, identifies malignant 
ventricular tachyarrhythmias and then delivers electri-
cal countershock to restore normal rhythm. There are 
two defibrillating electrodes which are also used for 
waveform analysis; one is located in the superior vena 
cava and the other is placed over the cardiac apex. A 
third bipolar right ventricular electrode is used for rate 
counting and R wave synchronization. When ventricular 
fibrillation occurs, a 25 J pulse is delivered; when ven-
tricular tachycardia faster than the preset rate is de-
tected, the discharge is R wave-synchronized. The clin-
ical evaluation study of this therapeutic method began 
in February 1980 in patients with recurrent refractory 
Management of patients with malignant ventricular arrhyth-
mias occurring outside the hospital continues to represent a 
formidable challenge. The early hopes placed in prophy-
lactic antiarrhythmic therapy have not yet materialized, and 
the delivery of a sufficiently strong electrical countershock 
remains the mainstay of any attempt to terminate ventricular 
fibrillation and many hemodynamically unstable ventricular 
tachycardias. 
Inasmuch as direct current cardioversion is critically de-
pendent on the rapid availability of medical personnel and 
equipment, its implementation outside the hospital is rarely 
successful. To address this problem, the concept of an im-
plantable, fully automatic device capable of identifying and 
treating life-threatening ventricular arrhythmias was brought 
forward (1,2). More than 10 years elapsed, however, before 
such a device could be developed and applied clinically (3). 
Today, the automatic implantable cardioverter-defibrillator 
is used with increasing frequency to prevent sudden ar-
rhythmic death in high risk patients. This article will review 
and summarize the accumulated clinical experience with this 
new therapeutic method (3-26). The preclinical phase of 
this work has been reviewed elsewhere (27,28). 
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life-threatening ventricular tachyarrhythmias. So far, 
the device has been implanted in nearly 500 patients with 
a follow-up period of up to 59 months. The risks and 
complications associated with this treatment were found 
to be moderate. Actuarial analysis has demonstrated 
significant impact on the survival rate of the patients 
receiving implants with 1 year arrhythmic mortality rate 
reduced to 2% or less in all groups analyzed. 
The available data indicate that the automatic car-
dioverter-defibrillator can reliably identify and correct 
potentially lethal ventricular tachyarrhythmias, leading 
to a substantial improvement in survival in properly 
selected high risk patients. 
(J Am Coli CardioI1985;6:461-6) 
The Device 
The automatic implantable cardioverter-defibrillator is a 
self-contained automatic system with extensive monitoring, 
diagnostic and therapeutic capabilities. It is an advanced 
version of the original automatic implantable defibrillator 
(AID, Intec Systems, Inc.) introduced into clinical practice 
in 1980 (3). While the original defibrillator was designed 
to correct only ventricular fibrillation, the new device also 
identifies and treats ventricular tachycardias. The addition 
of cardioverting capabilities has significantly increased the 
versatility and the clinical impact of the system. 
The new device consists of a pulse generator and three 
electrode leads. The pulse generator weighs 292 g and has 
a volume of 162 cc. It is housed in a hermetically-sealed 
titanium case containing the electronic components and power 
sources; the latter are expected to provide nearly 3 years of 
monitoring life or the delivery of about 100 discharges. Two 
transcardiac electrodes deliver the electrical countershock 
directly to the heart: one catheter electrode is incorporated 
into an intravascular catheter positioned in the superior vena 
cava, while the second, a flexible rectangular patch, covers 
the apex of the heart; these defibrillating electrodes also 
sense the configuration of the cardiac electrogram. The third 
lead is a separate catheter containing two closely spaced 
electrodes on its tip, which is wedged into the right ven-
tricular apex; it provides input signals for heart rate deter-
mination and R wave synchronization. Whenever the chest 
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is open during the implantation procedure, two epicardial 
screw-in electrodes can be substituted for this right ven-
tricular rate channel. 
The automatic implantable cardioverter-defibrillator 
continuously monitors and analyzes the patient's heart rate 
and waveform configuration (29). The latter is expressed in 
terms of the probability density function, which reflects the 
time spent by the electrical signal near the isoelectric line. 
The device makes the diagnosis of "treatment-requiring" 
arrhythmia when both the heart rate and probability density 
function exceed critical values, an event that initiates the 
capacitor charging cycle. When the charge on the capacitors 
reaches approximately 720 V, a truncated exponential pulse 
(30) of 25 J is delivered approximately 17 seconds from 
arrhythmia onset. In the presence of ventricular tachycardia, 
the pulse delivery is synchronous with the R wave. If the 
initial discharge does not terminate the abnormal rhythm, 
the device delivers additional pulses of 30 J each; up to 
three recyclings may occur during a single arrhythmic ep-
isode. Devices with higher energy outputs also are available 
for use in patients with increased defibrillation threshold. 
The pulse generator can be deactivated and reactivated at 
will with the proper use of a magnet. 
In addition to the standard automatic implantable car-
dioverter-defibrillator characterized by the dual detection 
algorithm, a variant of the device which features a sensing 
system that relies only on the analysis of heart rate is also 
available. This "rate only" version of the cardioverter-
defibrillator preferred by some investigators (17-20), is more 
sensitive than the standard unit and theoretically less likely 
to miss ventricular tachycardias with narrow QRS com-
plexes, but it will also deliver pulses during supraventricular 
arrhythmias that are faster than the present rate cutoff value 
of the device. 
Testing the device. This outline of the basic structural 
and functional characteristics of the system would not be 
complete without mentioning techniques for noninvasively 
communicating with the cardioverter-defibrillator. By mag-
netically triggering coded audio signals generated by a built-
in piezoelectric transducer and by using a specially designed 
device, the AIDCHECK (Intec Systems, Inc.), it is possible 
to interrogate the automatic implantable cardioverter-
defibrillator and to obtain information about such clinically 
important variables as the integrity of the sensing function, 
the status (active or inactive) of the pulse generator, the 
degree of battery depletion, capacitor deformation and the 
cumulative number of pulses that the unit has delivered to 
the patient. These tests are performed before, during and 
after implantation. 
The Clinical Study 
The clinical evaluation of the automatic implantable de-
fibrillator and subsequently of the automatic implantable 
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cardioverter-defibriIlator began in February 1980 with the 
first implantation of the device in a human being (3). Carried 
out initially on a limited number of patients, first at The 
Johns Hopkins Hospital and later at Stanford University 
Hospital, Stanford, California, the study followed rigidly 
defined criteria and centered on a careful search for weak 
links in the implanted system. As a direct corollary of this 
effort, many improvements have been incorporated into the 
device, better patient selection guidelines have been defined 
and new procedures and testing techniques have been de-
veloped. Encouraging clinical results led to progressive ex-
pansion of the study to additional institutions in this and 
other countries. By the end of 1984, the number of patients 
who had received an implant was 488; 5,433 pulse generator 
implant-months had been accumulated; the longest follow-
up was 59 months and the mean follow-up was slightly 
greater than 11 months. 
Patient group. Selection of patients. Only patients 
identified as being at extremely high risk of dying from 
refractory malignant arrhythmias were considered candi-
dates for the procedure. Initially, the patients who were to 
receive implants were required to have had at least two 
previous cardiac arrests not associated with acute myo-
cardial infarction; one such episode had to occur despite 
drug therapy and with the malignant arrhythmia documented 
at least once. Patients were excluded if their life expectancy 
was significantly limited by noncardiac disease, if they were 
receiving drugs (other than antiarrhythmic drugs) known to 
influence electrical activity of the heart or if psychologic 
disabilities were present. However, evidence of advanced 
left ventricular dysfunction was never a contraindication for 
the procedure. 
Currently, the criteria for implantation have become 
somewhat less stringent. For a patient to be considered for 
the procedure, only a single episode of ventricular fibril-
lation or hemodynamically unstable ventricular tachycardia 
occurring outside the context of acute myocardial infarction 
is required, provided that there is evidence of incomplete 
protection by antiarrhythmic drugs, as determined by ar-
rhythmia inducibility during electrophysiologic or stress testing 
or by the inability to suppress complex ventricular arrhyth-
mias on Holter monitor recordings. 
Patient characteristics. This relative relaxation of the 
entry criteria into the study has done little to change the 
clinical and demographic characteristics of the patient group. 
Survivors of recurrent cardiac death still form the great 
majority of patients receiving implants; for example, the 
average number of arrhythmic cardiac arrests in 112 patients 
operated on through September 1984 at The Johns Hopkins 
and Sinai Hospitals in Baltimore is 3.5 (the two Institutions 
hereafter will be referred to as Hopkins). The clinical profile 
of this group seems to be similar to that of patients operated 
on at other centers. There were 85 men and 27 women 
whose ages ranged between 16 and 76 years (mean 53). 
The average ejection fraction was 32%. Eighty-five patients 
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had coronary artery disease and 23 had nonischemic car-
diomyopathy. Prolonged QT interval was present in two and 
the remaining two patients had primary electrical disease. 
Before implantation, these patients failed aggressive med-
ical and surgical management and had not responded (on 
average) to 4.5 antiarrhythmic drugs; 15 patients were treated 
with coronary bypass grafting, 1 had a myectomy for relief 
of hypertrophic sub aortic stenosis and 10 had had a per-
manent electronic pacemaker implanted. 
Surgical Approaches 
Whereas the superior vena cava and the right ventricular 
electrode catheters were introduced into their intended lo-
cation using the conventional pervenous technique, proper 
placement of the apical patch electrode requires a surgical 
approach. Initially, a median sternotomy or a left lateral 
thoracotomy was employed for this purpose (14). Subse-
quently, simpler techniques were developed. The subxi-
phoid approach, for example, uses a small incision below 
the xiphoid process to enter the pericardial space anteriorly, 
allowing the patch electrode to be extended laterally over 
the apex and sutured proximally to the pericardium (15). 
More recently, a subcostal approach has also been suggested 
(21). This technique combines the advantages of a relatively 
minor surgical procedure with excellent exposure of the left 
ventricle. Whichever technique is selected, the leads are 
channeled under the skin and connected to the pulse gen-
erator placed in a paraumbilical pocket. 
In some centers, a thoracotomy is the preferred surgical 
approach because it provides the best possible exposure for 
placement of the patch or even of two patches, which are 
occasionally necessary to achieve effective defibrillation 
(17-20,22). At Hopkins, the choice of the implantation 
technique is determined by clinical circumstances. Thus, 
median sternotomy is performed when the implantation pro-
cedure is associated with corrective open heart surgery, 
whereas the subxiphoid and subcostal approaches are re-
served for patients in whom concomitant cardiac surgery is 
not indicated. Lateral thoracotomy is used to avoid scar 
tissue in patients who previously underwent cardiac surgery 
by sternotomy. 
Concomitant cardiovascular surgery. Whenever in-
dicated, implantation of the automatic implantable cardio-
verter-defibrillator at Hopkins was associated with addi-
tional cardiac and particularly antiarrhythmic surgery. In 
the previously mentioned series of 112 patients receiving 
implants, 26 underwent mapping-directed endocardial re-
section, associated in 17 with an aneurysmectomy and in 
13 with coronary artery bypass grafting. Another 13 patients 
had only coronary bypass grafting, and I of these had mitral 
valve replacement. The rationale behind combining im-
plantation of the device with other cardiac procedures is to 
provide the patient with optimal protection from the lethal 
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arrhythmia. For example, endocardial resection markedly 
reduces the number of subsequent arrhythmic events but 
does not eliminate them in all cases because of incomplete 
ablation of the arrhythmogenic foci or progression of the 
underlying disease process (16). Approximately 20% of the 
Hopkins patients who underwent antiarrhythmic surgery had 
recurrences of malignant arrhythmias, with the automatic 
implantable cardioverter-defibrillator providing them with a 
unique backup system to ensure their long-term safety (25). 
There is no hard evidence to indicate that coronary artery 
bypass grafting plays a role in the prevention of sudden 
arrhythmic death. However, improved vascularization of the 
heart could be expected, at least on theoretical grounds, to 
decrease or even eliminate myocardial ischemia capable of 
triggering a lethal arrhythmia. 
Electrophysiologic Evaluation 
Before implantation, electrophysiologic testing using 
programmed electrical stimulation is performed to determine 
the inducibility of ventricular arrhythmias and the charac-
teristics of those induced. During implantation, output sig-
nals from the transcardiac leads and from the rate channel 
are recorded and analyzed; at Hopkins, lead impedance is 
also routinely calculated. Malignant arrhythmias are then 
induced with low level alternating current (13) and the amount 
of energy required for their termination is measured with 
an external, nonautomatic pulse generator that uses a wave-
form identical to that of the automatic inducible cardio-
verter-defibrillator. The determination of the defibrillation 
threshold has so far been shown to be a safe procedure, 
extremely helpful for proper selection of the type of leads 
to be used, their optimal locations and of the characteristics 
of the device to be implanted (10,18). After implantation, 
the patient's malignant arrhythmia is reinduced and the au-
tomatic functions of the device are tested. No patient is 
discharged from the hospital with this device unless its life-
saving capability has been demonstrated. 
Functional Variables 
The ability of the automatic implantable cardioverter-
defibrillator to perform its tasks has been studied in a variety 
of clinical settings. The monitoring capabilities of the sys-
tem, the reliability of arrhythmia recognition and the effec-
tiveness and ease of arrhythmia termination have been sub-
jected to particularly close scrutiny. The great majority of 
the implanted pulse generators achieved their predicted 
monitoring life in accordance with specifications. However, 
accelerated battery depletion was observed in some 9% of 
the devices. The problem was traced to corrosion of the 
glass insulator in the feedthrough connectors of the battery 
and has been corrected by application of a protective coating. 
The diagnostic accuracy of the device has been found to 
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be exceLLent. In the controlled conditions of the electrophys-
iology laboratory, induced ventricular fibrillation and ven-
tricular tachycardia were correctly identified in 99% of the 
cases (26). When the proper diagnosis was not made, the 
cause was easily recognized and corrected. The handful of 
false negative diagnoses was usually due to lead malposi-
tion, 60 cycle interference or interaction with an implanted 
unipolar pacemaker. 
Termination of the malignant arrhythmias was generally 
accomplished with a single 25 J internal discharge; in rare 
instances, one or more recyclings were necessary to ter-
minate the abnormal rhythm. The time from the induction 
of the arrhythmia until its termination ranged between II 
and 36 seconds (average 17). Postdischarge bradycardias 
were rarely observed. 
High threshold. Because of a high defibrillation thresh-
old, standard 25 J discharges delivered through the superior 
vena cava patch lead configuration were ineffective in re-
storing normal rhythm in 12% of patients. The increased 
threshold could not clearly be related to underlying cardiac 
disease process, size of the heart or extent of left ventricular 
dysfunction (18). In some patients, when high threshold 
was associated with hypokalemia or amiodarone therapy, 
an appropriate electrolyte or pharmacologic adjustment low-
ered energy requirements (9,24). In others, the problem was 
remedied by replacing the standard patch electrode with one 
of a larger size, substituting a second patch electrode for 
the superior vena cava electrode or searching for more ef-
fective lead positions. In particularly difficult cases, im-
plantation of a high energy output pulse generator was 
required. 
Subjective reactions. The internal discharges were gen-
erally well tolerated, even when delivered to conscious pa-
tients. The subjective reactions ranged from lack of any 
perceptible sensation to a very painful one, but most of the 
patients receiving the implants described the discharge as a 
moderate blow to the chest resulting in a momentary dis-
comfort. No serious emotional problems were observed among 
the Hopkins patients receiving implants; however, Stanford 
investigators (20) reported a different experience in patients 
who had received a large number of discharges within a 
very short period of time. In the presence of frequent re-
petitive shocks, it is advisable to temporarily deactivate the 
unit and stabilize the rhythm in a hospital setting with phar-
macologic and other means. 
Control of acceleration. Clinical observations also have 
demonstrated the ability of the device to deal effectively 
with the phenomenon of acceleration, which can occur 
whenever ventricular tachycardia is treated electrically with 
external or transvenous cardioversion (31), antitachycardia 
pacing (32) or the automatic implantable cardioverter-
defibrillator. Under these circumstances the tachycardia, rather 
than being terminated, may accelerate into a faster, usually 
less organized rhythm or even degenerate into ventricular 
JACC Vol. 6, No.2 
August 1985:461-6 
fibrillation. This unpredictable development can be observed 
at all energy levels (18). Although synchronization of the 
discharge to the R wave decreases the incidence of accel-
eration, it does not eliminate the phenomenon completely. 
The cardioverter-defibrillator is the only implantable anti-
tachycardia system capable of controlling acceleration au-
tomatically through recycling: the device recognizes the ac-
celerated rhythm de novo and corrects it with one or more 
subsequent discharges. Several examples of accelerated 
rhythms so terminated by the device have been reported 
(6,7). 
Complications 
The risks and complications observed during the clinical 
evaluation study of the automatic implantable cardioverter-
defibrillator comprise a broad spectrum. As a result of close 
clinical and engineering interaction, the great majority of 
problems have been solved and are now of historic interest 
only. Currently, two potential risk areas should be consid-
ered whenever implantation is being contemplated, one re-
lated to the methods employed and the other reflecting the 
design characteristics of the device. 
Surgical complications. Among the risks related to 
methods, surgical complications are the most important. In 
the Hopkins series of 112 patients receiving implants, I 
operative death occurred as a result of perforation of the 
subclavian vein by a polyethylene central catheter. Infection 
occurred in six patients: in four the primary site was the 
pulse generator pocket, in one it was located at the ante-
cubital cutdown site while in another the origin of infection 
was unknown. In two cases of infection, complete expla-
nation of the system was required. Postoperative bleeding 
necessitated transfusions in two patients. Occasional ac-
cumulation of sterile fluid in the pulse generator pocket was 
always uneventfully reabsorbed. Transient pericardial rubs 
were the rule after implantation. One episode of superior 
vena cava thrombosis responded well to anticoagulant drugs, 
but no embolic phenomena were noted. Lead dislodgment 
requiring repositioning occurred in seven patients; recently, 
better fixation techniques have reduced the incidence of this 
complication. No adverse effects related to electrophysio-
logic testing were observed. 
Malfunction. The new technology behind the automatic 
implantable cardioverter-defibrillator has given rise to a dif-
ferent set of problems. As with any complex system, mal-
function may occur. The types of malfunction observed 
during this study include hermeticity loss, breakdown of the 
gaseous dielectric, misdirection of the battery testing pulse 
toward the patient and random component failure. These 
complications were rare and did not result in permanent 
harm. 
Particularly significant from a clinical viewpoint are false 
positive discharges. In the early stages of the study, spurious 
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signals generated by fractured leads or miscounting of the 
heart rate caused most of the oversensing. With improve-
ments in lead construction and the introduction of a separate 
rate channel, spurious discharges due to these causes have 
been virtually eliminated. 
Today, oversensing may still occur as a result of inter-
action of an implanted unipolar pacemaker with the device 
(23) or particularly fast supraventricular arrhythmias that 
satisfy the sensing algorithm of the device. Pulse delivery 
during sinus rhythm can also be caused by nonsustained 
ventricular tachycardias. Although the sensing function in 
these instances is entirely appropriate, once the diagnosis 
is made and the capacitor charging cycle initiated, the device 
is committed to discharge, even if sinus rhythm has been 
restored in the interim. 
Prevention of unwanted discharges during sinus 
rhythm. Although these have not induced significant ar-
rhythmias or resulted in any other serious effects, they are 
clearly undesirable. The incidence of such discharges can 
be decreased by implementing a few simple clinical mea-
sures. The automatic implantable cardioverter-defibrillator 
to be implanted should have a cutoff rate that is greater than 
that of the patient's fastest sinus rhythm and less than the 
rate of his or her ventricular arrhythmia. Moreover, phar-
macologic interventions can be used after implantation to 
modify the patient's rhythm favorably. In patients who re-
quire treatment with both this device and a pacemaker, only 
a bipolar rather than a unipolar pacemaker should be used. 
Frequent nonsustained ventricular tachycardias should also 
be controlled with antiarrhythmic medication. During in-
traoperative electrocautery and in the immediate postoper-
ative period when supraventricular tachyarrhythmias fre-
quently occur, the device should be temporarily deactivated. 
Mortality 
Because the chief objective of the automatic implantable 
cardioverter-defibrillator is to prevent sudden arrhythmic 
death, it is appropriate to examine the impact, if any, this 
therapeutic intervention has had on the mortality rate of the 
patients receiving implants. The unique clinical character-
istics of the study group and its relatively rapid growth have 
already made this information available. 
The initial data were derived from the analysis of the 
first 52 patients receiving implants, 42 from Hopkins and 
IO from Stanford, the great majority of whom were treated 
with the original automatic implantable defibrillator device 
(5). Kaplan-Meier survival curves in this group indicated a 
total 1 year mortality rate of 22.9% and an arrhythmic I 
year mortality rate of 8.5%. With the increase in the number 
of patients receiving implants, it was soon possible to com-
pare the respective effectiveness of the original defibrillator 
with the new one, which treats both ventricular fibrillation 
and ventricular tachycardia. At I year follow-up, the ar-
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rhythmic mortality rate of 32 patients who received the 
original device was 10.6%, and in the 67 patients treated 
with the new device it was only 2%; the total I year mortality 
rate was 26 and 16.6%, respectively (7). Virtually identical 
figures were subsequently found in a larger Hopkins series 
of 112 patients (II). 
Survival analysis was also performed in a series of 70 
patients treated mainly with the "rate only" type of auto-
matic implantable cardioverter-defibrillator at Stanford Uni-
versity Hospital (20). In this series, Kaplan-Meier curves 
revealed an arrhythmic I year mortality rate of 1.8%. The 
manufacturer of the device has recently reported to the U. S. 
Food and Drug Administration data from 323 patients re-
ceiving implants (a group that overlaps with the previously 
described Hopkins and Stanford series) (26). These data 
were also analyzed in accordance with the type of device 
the patients received: the I year arrhythmic mortality rate 
was 11.9% in 37 patients treated with an automatic im-
plantable defibrillator, 1.9% in 209 patients treated with the 
standard automatic implantable cardioverter-defibrillator and 
1.3% in 95 patients who received the "rate only" cardio-
verter -defibrillator. 
All of these results are remarkably concordant. While 
the expected mortality rate of the types of patients included 
in the study ranged, according to various historical controls, 
between 27 and 66% (33-39), the model that treated only 
ventricular fibrillation decreased the I year arrhythmic mor-
tality rate to approximately 11%. On the other hand, the 
improved, currently used automatic implantable cardio-
verter-defibrillator model reduced this mortality rate to 2% 
or less, virtually eradicating sudden arrhythmic death during 
the year after implantation of the device. 
Conclusion 
During the past 5 years, automatic implantable defibril-
lating systems have been evaluated for safety and efficacy. 
The automatic implantable cardioverter-defibrillator, the most 
recent generation of the device, has been shown capable of 
reliably monitoring the heart for prolonged periods of time, 
identifying ventricular fibrillation and the broad spectrum 
of ventricular tachycardias and terminating them with an 
internal countershock. The risks and complications asso-
ciated with the use of the device have been minimal. The 
available evidence indicates that implantation of this device 
dramatically decreases the incidence of sudden arrhythmic 
death in the so treated high risk patients. 
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